| GC (N = 2) | MTX (N = 6) | IL1 Inhibitor (N = 12) | IL6 Inhibitor (N = 10) | Total (N = 30) | P-value |
---|---|---|---|---|---|---|
Age in yearsa | 12.8 | 3.4 | 4.0 | 9.8 | 5.7 | 0.047 |
Female | 50% | 67% | 92% | 90% | 83% | 0.3 |
White | 0% | 83% | 33% | 80% | 57% | 0.03 |
Disease duration (days)a | 121 | 38 | 31 | 55 | 42.5 | 0.2 |
Polyarthritis | 0% | 50% | 67% | 80% | 63% | 0.18 |
Number of active jointsa | 1.0 | 4.5 | 5.0 | 5.5 | 4.0 | 0.28 |
ESR >3x ULN | 100% | 67% | 91% | 43% | 73% | 0.27 |
CRP >3x ULN | 100% | 83% | 91% | 40% | 79% | 0.28 |
Ferritin (ng/mL)a | 12,874 | 1,394 | 1,062 | 627 | 783 | 0.09 |
CHAQ scorea | 0.9 | 1.3 | 1.9 | 0.8 | 1.4 | 0.6 |
Pain score (0–10)a | 3 | 6.5 | 6 | 7.5 | 6 | 0.6 |
Physician global assessment (0–10)a | 4 | 7 | 5 | 5 | 5.5 | 0.12 |
Parent global assessment well-being (0–10)a | 0 | 7 | 6 | 6 | 6 | 0.103 |
Initiated GC at baseline | 100% | 100% | 42% | 70% | 67% | 0.029 |
Initial GC dose (mg/kg)a | 0.67 | 0.97 | 0.00 | 0.68 | 0.80 | 0.548 |
GC prior to baseline | 50% | 16.7% | 8.3% | 30% | 20% | 0.350 |
Initial dose of each CTP medication in mg/kg (IQR)a | 0.67 (0.6–0.73) | 0.487 (0.46–0.64) | 2.93 (2–3.6)b | 8.14 (8–12) | Not Applicable |  |